基于外周血EGFR突变检测临床意义的深度思考教材_课件.pptVIP

基于外周血EGFR突变检测临床意义的深度思考 北京大学临床肿瘤学院 北京肿瘤医院 IPASS Study:Progression-free survival by EGFR mutation type (ITT population) Post-hoc Cox analysis with covariatesp-values not calculated due to small patient numbers Exon 19 deletion L858R Time from randomization (months) HR (95% CI) = 0.377 (0.255, 0.560) No. events gefitinib, 46 (69.7%)No. events C/P, 65 (87.8%) Gefitinib (n=66)Carboplatin/paclitaxel (n=74) HR (95% CI) = 0.553 (0.352, 0.868)No. events gefitinib, 48 (75.0%)No. events C/P, 40 (85.1%) 66 40 18 6 2 0 74 15 4 2 1 0 61 56 0 4 8 12 16 20 24 Gefitinib C/P Patients at risk :